Edwards Lifesciences Corp (EW)

Industry Medical Devices

This stock can be held in an Investment ISA and an Investment Account

Sell

$75.00

Buy

$80.00

arrow-up$0.62 (+0.80%)

Prices updated at 31 May 2025, 00:32 EDT

Prices minimum 15 mins delay

Prices in USD

Edwards Lifesciences Corp is a part of the healthcare sector. The company specializes in the treatment of structural heart disease. It manufactures heart valves and repair products used to replace or repair a patient's diseased or defective heart valve.

S&P 500

-0.01%

NYSE

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Medical Devices

Chairman

Mr. Nicholas J. Valeriani

CEO

Mr. Bernard J. Zovighian

Most recent earnings

31 Dec 2024

Fiscal year end

31 Dec 2024

Employees

15,800

Head office

One Edwards Way

Irvine

United States

92614

+1 949 250-2500

investor_relations@edwards.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Mr. Donald E. Bobo,Jr Corporate Vice President	0.74m
Mr. Kieran T. Gallahue Independent Director	0.09m
Mr. Larry L. Wood Corporate Vice President and Group President, Transcatheter Aortic Valve Replacement and Surgical Structural Heart	0.78m
Mr. Nicholas J. Valeriani Chairman of the Board	0.09m
Mr. Paul A. Laviolette Independent Director	0.11m
Mr. Steven R. Loranger Independent Director	0.09m
Ms. Leslie Stone Heisz Independent Director	0.12m
Mr. Scott B. Ullem Corporate Vice President and Chief Financial Officer	0.77m
Dr. David T. Feinberg, M.D.,PhD Director	0.08m
Mr. Bernard J. Zovighian Director and Chief Executive Officer	1.13m
Mr. Daveen Chopra Corporate Vice President, Transcatheter Mitral and Tricuspid Therapies	0.63m
Ms. Ramona A. Sequeira Independent Director	0.09m
Mr. Wayne Markowitz General Manager and Senior Vice President, Surgical Structural Heart	-
Ms. Annette Bruls Corporate Vice President, EMEACLA	-
Mr. Daniel J. Lippis Corporate Vice President, JAPAC	-
Ms. Leslie C. Davis Independent Director	0.09m
Mr. Andrew M. Dahl Principal Accounting Officer, Senior Vice President and Corporate Controller	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
Vanguard Group Inc	69,198,828
Vanguard Group Inc. ( Junked)	62,594,108
BlackRock Inc	54,711,593
Wellington Management Company LLP	29,134,790
State Street Corp	25,783,462

Director dealings

Date chevron-l-regular chevron-r-regular	Action
16 Dec 2024	-
16 Dec 2024	-
16 Dec 2024	-
09 Dec 2024	-
09 Dec 2024	-
09 Dec 2024	-
09 Dec 2024	-
09 Dec 2024	-
09 Dec 2024	-
06 Dec 2024	-
06 Dec 2024	-
13 Nov 2024	-
13 Nov 2024	-
13 Nov 2024	-
05 Nov 2024	-
15 Oct 2024	-
15 Oct 2024	-
15 Oct 2024	-
14 Sep 2024	-
13 Sep 2024	-

Please note that past performance is not a reliable indicator of future returns.

Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.